1. Home
  2. PRPO vs KZIA Comparison

PRPO vs KZIA Comparison

Compare PRPO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • KZIA
  • Stock Information
  • Founded
  • PRPO N/A
  • KZIA 1994
  • Country
  • PRPO United States
  • KZIA Australia
  • Employees
  • PRPO N/A
  • KZIA N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRPO Industrials
  • KZIA Health Care
  • Exchange
  • PRPO Nasdaq
  • KZIA Nasdaq
  • Market Cap
  • PRPO N/A
  • KZIA 5.1M
  • IPO Year
  • PRPO N/A
  • KZIA 1999
  • Fundamental
  • Price
  • PRPO $11.18
  • KZIA $6.51
  • Analyst Decision
  • PRPO
  • KZIA Strong Buy
  • Analyst Count
  • PRPO 0
  • KZIA 2
  • Target Price
  • PRPO N/A
  • KZIA $57.50
  • AVG Volume (30 Days)
  • PRPO 9.8K
  • KZIA 2.6M
  • Earning Date
  • PRPO 08-12-2025
  • KZIA 07-07-2025
  • Dividend Yield
  • PRPO N/A
  • KZIA N/A
  • EPS Growth
  • PRPO N/A
  • KZIA N/A
  • EPS
  • PRPO N/A
  • KZIA N/A
  • Revenue
  • PRPO $20,029,000.00
  • KZIA $1,549,158.00
  • Revenue This Year
  • PRPO N/A
  • KZIA N/A
  • Revenue Next Year
  • PRPO N/A
  • KZIA N/A
  • P/E Ratio
  • PRPO N/A
  • KZIA N/A
  • Revenue Growth
  • PRPO 26.67
  • KZIA 248983.08
  • 52 Week Low
  • PRPO $3.90
  • KZIA $2.86
  • 52 Week High
  • PRPO $11.80
  • KZIA $79.00
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 58.62
  • KZIA 49.53
  • Support Level
  • PRPO $10.82
  • KZIA $6.00
  • Resistance Level
  • PRPO $11.70
  • KZIA $9.60
  • Average True Range (ATR)
  • PRPO 0.57
  • KZIA 1.16
  • MACD
  • PRPO -0.15
  • KZIA -0.32
  • Stochastic Oscillator
  • PRPO 52.31
  • KZIA 15.84

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: